Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arestin in Peri-Implantitis
NCT01539564Phase 3
Key facts
- Status
- Completed
- Start
- Apr 2012
- Primary completion
- May 2014
- Countries
- 4
- Sponsor
- OraPharma
- Modality
- Small Molecules
- Drugs
- minocycline
- Conditions
- peri-implantitis
01
Overview
Phase 3, randomised, single-blind trial of minocycline in peri-implantitis, sponsored by OraPharma. Primary endpoint: Change in mean Probing Depth at 180 days. Started Apr 2012; status: completed.
02
Design
- Study design
- RandomizedSingle-blind
03
Who it enrols
Subjects with osseointegrated implants diagnosed with peri-implantitis, featuring probing depths of 5-7mm, bleeding on probing, and confirmed pathologic bone loss.
04
Endpoints
Primary
Change in mean Probing Depth
Beyond the preview
Go deeper on NCT01539564.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01539564.